Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role

Journal of Pharmaceutical Sciences

Volumn 98, Issue 6, 2009, Pages 2198-2211

  Agoram, Balaji ^a   Aoki, Ken ^a   Doshi, Sameer ^a   Gegg, Colin ^a   Jang, Graham ^a   Molineux, Graham ^a   Narhi, Linda ^a   Elliott, Steve ^a  

^a AMGEN INC   (United States)

Author keywords

Carbohydrate; Clearance; Erythropoietin; Erythropoietin receptor; Glycosylation; Pegylation; Pharmacokinetics; Physicochemical properties; Protein engineering; Proteins

Indexed keywords

CARBOHYDRATE; ERYTHROPOIETIN; MACROGOL DERIVATIVE; NM 385; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SENSITIVITY; FEMALE; HUMAN; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR BINDING;

EID: 67049136371     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21578     Document Type: Article

References (47)

1. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. 2002. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110-118. (Pubitemid 34701218)
2. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J. 2002. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220. (Pubitemid 34993871)
3. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA. 1991. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712.
4. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. 2003. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299. (Pubitemid 36407605)
5. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I. 2004. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32:1146-1155. (Pubitemid 39601120)
6. Sinclair AM, Elliott S. 2005. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94:1626-1635. (Pubitemid 41360859)
7. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. 1999. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395. (Pubitemid 29501473)
8. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. 2003. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421. (Pubitemid 36397662)
9. Jolling K, Ruixo JJ, Hemeryck A, Piotrovskij V, Greway T. 2004. Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J Pharm Sci 93:3027-3038. (Pubitemid 39657806)
10. Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN. 2006. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Exp Hematol 34:697-704. (Pubitemid 43737103)
11. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. 2006. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1:1211-1215.
12. Fukuda MN, Sasaki H, Lopez L, Fukuda M. 1989. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73:84-89. (Pubitemid 19040958)
13. Spivak JL, Hogans BB. 1989. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73:90-99. (Pubitemid 19040959)
14. 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 279:1205-1210.
15. Jensen JD, Jensen LW, Madsen JK, Poulsen L. 1995. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 54:111-116.
16. Lasne F, de Ceaurriz J. 2000. Recombinant erythropoietin in urine. Nature 405:635. (Pubitemid 30428640)
17. Catlin DH, Breidbach A, Elliott S, Glaspy J. 2002. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48:2057-2059. (Pubitemid 35222769)
18. Fu JS, Lertora JJ, Brookins J, Rice JC, Fisher JW. 1988. Pharmacokinetics of erythropoietin in intact and anephric dogs. J Lab Clin Med 111:669-676. (Pubitemid 18159164)
19. Kindler J, Eckardt KU, Ehmer B, Jandeleit K, Kurtz A, Schreiber A, Scigalla P, Sieberth HG. 1989. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 4:345-349. (Pubitemid 19189333)
20. Macdougall IC, Roberts DE, Coles GA, Williams JD. 1991. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 20:99-113.
21. Sawyer ST, Krantz SB, Goldwasser E. 1987. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262:5554-5562.
22. Gross AW, Lodish HF. 2006. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281:2024-2032. (Pubitemid 43845790)
23. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. 2001. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298:820-824. (Pubitemid 32673436)
24. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. 2004. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 25:149-156. (Pubitemid 38765288)
25. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G. 2005. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 41:1140-1149. (Pubitemid 40725572)
26. Kuwabara T, Kato Y, Kobayashi S, Suzuki H, Sugiyama Y. 1994. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans. J Pharmacol Exp Ther 271:1535-1543. (Pubitemid 24382668)
27. Bauer RJ, Gibbons JA, Bell DP, Luo ZP, Young JD. 1994. Nonlinear pharmacokinetics of recombinant humanmacrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exp Ther 268:152-158. (Pubitemid 24039082)
28. Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller GA, de Sauvage FJ, Eaton D. 1997. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 89:2782-2788. (Pubitemid 27172563)
29. Macdougall IC. 2005. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4:436-440.
30. Komatsu N, Yamamoto M, Fujita H, Miwa A, Hatake K, Endo T, Okano H, Katsube T, Fukumaki Y, Sassa S, et al. 1993. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood 82:456-464. (Pubitemid 23206108)
31. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. 1997. Mapping of the active site of recombinant human erythropoietin. Blood 89:493-502. (Pubitemid 27051684)
32. Kinstler OGC, Freeman A, Boone T. 2003. Inventors, Amgen Inc., Thousand Oaks, CA, USA, assignee Chemically modified novel erythropoiesis-stimulating protein compositions and methods. US Patent 6,586,398 B1 July 01, 2003.
33. Pacifici RE, Thomason AR. 1994. Hybrid tyrosine kinase/cytokine receptors transmit mitogenic signals in response to ligand. J Biol Chem 269:1571-1574. (Pubitemid 24035338)
34. Elliott S, Chang D, Delorme E, Dunn C, Egrie J, Giffin J, Lorenzini T, Talbot C, Hesterberg L. 1996. Isolation and characterization of conformation sensitive antierythropoietin monoclonal antibodies: Effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure. Blood 87:2714-2722. (Pubitemid 26102220)
35. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E, Giffin J, Hesterberg L. 1996. Fine-structure epitope mapping of antierythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure. Blood 87:2702-2713. (Pubitemid 26102219)
36. Gibaldi MPD. 1982. Pharmacokinetics. editor. New York: Marcel Dekker, Inc.
37. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM. 1998. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511-516. (Pubitemid 28462447)
38. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. 1996. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 35:1681-1691. (Pubitemid 26055303)
39. Hartley C, Elliott S, Begley CG, McElroy P, Sutherland W, Khaja R, Heatherington AC, Graves T, Schultz H, Del Castillo J, Molineux G. 2003. Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: Optimized erythroid support with darbepoetin alpha. Br J Haematol 122:623-636. (Pubitemid 36995217)
40. Heatherington AC, Schuller J, Mercer AJ. 2001. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: Preliminary report. Br J Cancer 84:11-16. (Pubitemid 32453430)
41. Briddell RSG, Sutherland W, Argento J, Kern B, Begley G, Molineux G. 2003. An in vitro investigation of the mode of clearance of erythropoietin by human bone marrow cells. Exp Hematol 31:214. [abstract 246].
42. Piroso E, Erslev AJ, Flaharty KK, Caro J. 1991. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 36:105-110.
43. Chen SY, Cressman S, Mao F, Shao H, Low DW, Beilan HS, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Savatski L, Adamson JW, Bozzini CE, Kung A, Kent SB, Bradburne JA, Kochendoerfer GG. 2005. Synthetic erythropoietic proteins: Tuning biological performance by site-specific polymer attachment. Chem Biol 12:371-383. (Pubitemid 40406284)
44. Kochendoerfer G. 2003. Chemical and biological properties of polymer-modified proteins. Expert Opin Biol Ther 3:1253-1261. (Pubitemid 38004696)
45. Yamaoka T, Tabata Y, Ikada Y. 1994. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83:601-606. (Pubitemid 24222392)
46. Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, Braeckman RA. 2000. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther 293:248-259. (Pubitemid 30180946)
47. Porter CJ, Edwards GA, Charman SA. 2001. Lymphatic transport of proteins after s.c. injection: Implications of animal model selection. Adv Drug Deliv Rev 50:157-171. (Pubitemid 32727281)